<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005984</url>
  </required_header>
  <id_info>
    <org_study_id>1996LS183</org_study_id>
    <secondary_id>UMN-MT-1996-11</secondary_id>
    <nct_id>NCT00005984</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia</brief_title>
  <official_title>Autologous Marrow Transplantation for Chronic Myelogenous Leukemia Using Stem Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving colony-stimulating factors, such as G-CSF, and cyclophosphamide helps stem&#xD;
      cells move from the patient's bone marrow to the blood so they can be collected and stored.&#xD;
      Chemotherapy and radiation therapy is then given to prepare the bone marrow for the stem cell&#xD;
      transplant. The stem cells are returned to the patient to replace the blood-forming cells&#xD;
      that were destroyed by the chemotherapy and radiation therapy.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well cyclophosphamide plus filgrastim followed&#xD;
      by stem cell transplant works in treating patients with chronic phase or accelerated phase&#xD;
      chronic myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the clinical outcomes, survival, and morbidity of patients with chronic or&#xD;
           accelerated phase chronic myelogenous leukemia when treated with cyclophosphamide and&#xD;
           filgrastim (G-CSF) followed by autologous peripheral blood stem cell transplantation.&#xD;
&#xD;
        -  Determine whether priming with cyclophosphamide and filgrastim (G-CSF) increases the&#xD;
           fraction of benign Philadelphia chromosome negative hematopoietic progenitors in&#xD;
           peripheral blood stem cells (PBSC) and reduces the incidence of persistent or recurrent&#xD;
           leukemia after autologous transplantation with mobilized PBSC in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive priming therapy consisting of cyclophosphamide IV over 2 hours on&#xD;
      day 1 and filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until&#xD;
      completion of leukapheresis. Peripheral blood stem cells (PBSC) are collected between days&#xD;
      14-21.&#xD;
&#xD;
      Patients then receive preparative therapy for transplant consisting of cyclophosphamide IV&#xD;
      over 2 hours on days -7 and -6 and total body irradiation twice a day on days -4 through -1.&#xD;
      Patients receive the PBSC transplantation on day 0. Patients also receive G-CSF IV starting&#xD;
      on day 0 and continuing until blood counts recover. Patients then receive interferon alfa SQ&#xD;
      daily in the absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      Patients are followed at 3 weeks; then at 3, 6, 9, 12, and 18 months; and then annually for 5&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Not specified&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated as principal investigator [PI] left the university.&#xD;
  </why_stopped>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to hemopoietic recovery after transplantation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of the Philadelphia chromosome or the BCR/ABL gene abnormality in post-transplantation marrow samples</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to initial hospital discharge</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritransplantation toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at various time points</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause of death</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Patients with CML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated for chronic accelerated phase and/or chronic myelogenous leukemia (CML)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>intravenously over 2 hours on day 1 and on days -7 and -6</description>
    <arm_group_label>Patients with CML</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover</description>
    <arm_group_label>Patients with CML</arm_group_label>
    <other_name>NEUPOGEN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
    <description>Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression</description>
    <arm_group_label>Patients with CML</arm_group_label>
    <other_name>INTRON® A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Patients receive the PBSC transplantation on day 0.</description>
    <arm_group_label>Patients with CML</arm_group_label>
    <other_name>bone marrow transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>total body irradiation twice a day on days -4 through -1</description>
    <arm_group_label>Patients with CML</arm_group_label>
    <other_name>irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed chronic or accelerated phase chronic myelogenous leukemia&#xD;
             (CML)&#xD;
&#xD;
               -  Philadelphia chromosome positive OR&#xD;
&#xD;
               -  BCR/ABL rearrangement&#xD;
&#xD;
          -  Ineligible or refused to participate in ongoing allogeneic marrow donor transplant&#xD;
             protocols&#xD;
&#xD;
          -  70 and under&#xD;
&#xD;
          -  Performance status:&#xD;
&#xD;
               -  Age 65-70 years:&#xD;
&#xD;
               -  Karnofsky 80-100%&#xD;
&#xD;
               -  Under 65 years:&#xD;
&#xD;
               -  Karnofsky 90-100%&#xD;
&#xD;
          -  Renal:&#xD;
&#xD;
               -  Age 65-70 years:&#xD;
&#xD;
               -  Creatinine clearance greater than 60 mL/min (if creatinine at least 1.5 mg/dL)&#xD;
&#xD;
               -  Under 65 years:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
          -  Cardiovascular:&#xD;
&#xD;
               -  Age 65-70 years:&#xD;
&#xD;
               -  LVEF at least 45%&#xD;
&#xD;
          -  Pulmonary:&#xD;
&#xD;
               -  Age 65-70 years:&#xD;
&#xD;
               -  If history of smoking or respiratory symptoms, spirometry and DLCO must be&#xD;
                  greater then 50% of predicted&#xD;
&#xD;
          -  Normal organ function (excluding bone marrow)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blast crisis or post blast crisis&#xD;
&#xD;
          -  Severe fibrosis defined by bilateral trephine biopsies&#xD;
&#xD;
          -  Splenomegaly (below umbilicus) that does not respond to chemotherapy and/or&#xD;
             radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine M. Verfaillie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <name_title>Catherine Verfaille, MD</name_title>
    <organization>Masonic Cancer Center, University of Minnesota</organization>
  </responsible_party>
  <keyword>chronic phase myelogenous leukemia</keyword>
  <keyword>accelerated phase myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

